Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 8/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.33 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16645717 | 0.91 | MDK (0.50) | MDKLGALS3LGALS8LGALS4MMP13 | |
| SCHEMBL18473097 | 0.88 | MDK (0.41) | MDKLGALS3LGALS8LGALS4MMP13 | |
| SCHEMBL18494424 | 0.80 | MDK (0.47) | MDKLGALS3LGALS8LGALS4MMP13 | |
| SCHEMBL18494423 | 0.80 | MDK (0.47) | MDKLGALS3LGALS8LGALS4MMP13 | |
| SCHEMBL17849186 | 0.74 | LGALS3 (0.54) | LGALS3LGALS8LGALS4LGALS9CHIA | |
| SCHEMBL17849185 | 0.73 | LGALS3 (0.54) | LGALS3LGALS8LGALS4LGALS9CHIA | |
| SCHEMBL16641974 | 0.73 | LGALS3 (0.54) | LGALS3LGALS8LGALS4LGALS9CHIA | |
| SCHEMBL17849184 | 0.73 | LGALS3 (0.46) | MDKLGALS3LGALS8LGALS4LGALS9 | |
| SCHEMBL16641976 | 0.73 | LGALS3 (0.46) | MDKLGALS3LGALS8LGALS4LGALS9 | |
| SCHEMBL20175842 | 0.72 | LGALS3 (0.52) | LGALS3LGALS8LGALS4LGALS9CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370583-B2 | Coagulation factor VII polypeptides | NOVO NORDISK HEALTHCARE AG (CH) | 2016-06-21 | — | — | US | disclosed |
| US-9371370-B2 | Coagulation factor VII polypeptides | NOVO NORDISK HEALTHCARE AG (CH) | 2016-06-21 | — | — | US | disclosed |
| US-20150105321-A1 | COAGULATION FACTOR VII POLYPEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105321-A1 | COAGULATION FACTOR VII POLYPEPTIDES | F7, F13B, HABP2 | MDK 2724/4885LGALS3 2458/4885LGALS8 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.